Novacyt confirms end of Yourgene Taiwan disposal discussions
Novacyt announced on Tuesday that it had received formal notification from INEX Innovate terminating discussions around the acquisition of Yourgene Health Taiwan.
The AIM-traded firm noted that Yourgene Health initially announced the acquisition on 13 June 2023.
As a result of the termination, Yourgene's Taiwanese laboratory business would remain within the Novacyt group.
“The board does not consider the divestment material and will continue to evaluate a number of options in relation to the future of the Taiwanese laboratory business that offer the best value to all stakeholders,” the Novacyt board said in its statement.
At 1158 GMT, shares in Novacyt were down 5.77% at 47.35p.
Reporting by Josh White for Sharecast.com.
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.
The value of investments can fall and you may get back less than you invested.